Product Features Used to Promote Top-selling Cannabis Vape Products in An Online Retail Environment

Julia Chen-Sankey, Kathryn La Capria, Siyan Meng, Rosanna Mazzeo, Neha Vijayakumar, Alisa A. Padon, Kimberly G. Wagoner, Meghan B. Moran, Matthew Rossheim, Carla Berg, Kristina M. Jackson
doi: https://doi.org/10.1101/2024.11.13.24317258

ABSTRACT

Introduction Exposure to commercial marketing of cannabis vape products (CVPs) may encourage CVP use, yet little is known about how these products are marketed. This study examined marketing descriptions of CVPs’ functions and benefits in an online retail environment.

Methods Product descriptions from a sample of 343 CVPs from 78 top-selling cannabis brands in 2023 were obtained from a large cannabis e-commerce website. Each description was thematically coded based on the promoted product features.

Results The most frequently mentioned product feature was flavor profile and sensation (74.1%), including general and specific flavor descriptors (e.g., fruit flavors) and sensory experiences (e.g., sweet, spicy). Psychoactive effects were noted in 47.5% of the descriptions, detailing potency or effects such as feeling “high,” “stoned,” or “buzzed.” Product quality, such as “purity,” “natural,” or “organic,” was mentioned in 42.3% of the descriptions. Other product benefits described included mood enhancement (33.8%), reduced harm (24.2%), relaxation/tension reduction (23.9%), therapeutic effects (18.4%), focus/creativity (16.6%), convenience/discreetness (11.1%), socialization enhancement (6.7%), and physical performance enhancement (6.1%).

Discussion Some frequently promoted product features of CVPs, such as flavor and sensation and psychoactive effects, may particularly appeal to younger consumers for non-medical use. Meanwhile, attributes surrounding high product quality and reduced harm may reduce individuals’ perceived risks of CVP use and may violate state restrictions on therapeutic claims. Additional research assessing the influence of exposure to marketed product features on product perceptions and use behaviors among priority populations is needed to inform regulations and enforcement.

INTRODUCTION

As of 2024, more than 20 states in the U.S. have legalized non-medical cannabis.1 Moreover, a 2023 study showed that regular delta-9 THC products for smoking or vaping were being sold in 61% of smoke shops in states without legal non-medical cannabis retail.2 There are many different types of cannabis products, which are consumed in different ways, including combustibles (for smoking), vapes, edibles, topicals, tinctures, and ingestible pills/capsules, etc.3 The past few years have seen tremendous growth in cannabis vape products (CVP) used to inhale and exhale an aerosol or vapor made from cannabis concentrates or dry flowers that are heated in an electronic-powered device.4 In 2023, the sales of CVPs constituted 33% of the cannabis market in the U.S., ranking second after flower,5 and such market share is projected to increase over the next few years.6,7

CVP use is especially popular among youth and young adults in the U.S.8–10 In 2023, 14% and 20% of 12th graders reported past 30-day and past-year cannabis vaping, respectively.11 In the same year, 14% and 22% of young adults (ages 19-30) reported past 30-day and past-year cannabis vaping, respectively, substantially higher than midlife adults (ages 35-50; 6% and 9%, respectively).12 CVPs, just like other cannabis products, may have potential applications for acute symptom relief across multiple conditions (e.g., anxiety, depression, epilepsy, pain); however, they also pose physical and mental health risks along with negative social consequences.13–15 Specifically, long-term and regular use of cannabis has a high potential for abuse and dependence and is associated with increased risk of paranoia, anxiety, depression, and exacerbation of psychosis.16,17 Among young adults, frequent cannabis use may also lead to altered brain development, poor educational outcomes, and difficulties in transition to work and adult roles.18,19 Although vaping cannabis reduces the ingestion of smoke-related toxins and carcinogens,20,21 cannabis vaping has been shown to produce a larger concentration of PM2.5 than tobacco cigarettes,22 and endothelial function impairment from exposure to CVP vapor23 is similar to smoked cannabis and tobacco cigarettes.24

One major factor contributing to CVP use may be exposure to commercial marketing. Decades of research in other areas, including alcohol and tobacco marketing, have yielded conclusive evidence that marketing exposure leads to initiation and regular use of these products.25–29 Youth and adults in the U.S., particularly in the states where non-medical cannabis use is legal, are exposed to cannabis advertising, including CVP-specific advertising, through many channels (e.g., physical and online retailers, billboards, websites, and social media).30–36 More research on CVP marketing is needed to support the development of marketing policies and other intervention strategies that can effectively prevent youth initiation and reduce use.

Marketing theories such as the means-end approach posit that advertising strategies leverage tangible product features detailing the functionalities and benefits of the products (e.g., a CVP that “gets me high”) to shape individuals’ expectancies (the anticipated outcomes from using the products) and interest in using the marketed products.37,38 These product features often appeal to consumers’ psychological needs and motives for product use. Specifically, consumers form harm perceptions and outcome expectancies of product use based on how the product features are advertised and labeled.39–41 Indeed, research on nicotine vape product marketing found that product features (e.g., claims describing flavor sensation, smoking cessation benefits, and convenience) predict and influence the positive expectancies and interest in the use of nicotine vape products among young adults.42–47 The CVP industry promotes CVPs as “safer” or “healthier,” especially compared with smoking cannabis products, which can reduce perceptions of harm that may delay or prevent use among young people.48,32 However, little else is known ssssssabout the content and types of product features used for marketing CVPs. Much of the research assessing the characteristics of cannabis product features has grouped various types of cannabis products together and only examined a narrow range of features.49–51 One of the few studies that limited its investigation of product marketing descriptions to a single product type (cannabis flower) revealed that the dominant product features included relaxation, stress relief, and happiness.52 However, product features used for promoting CVPs are likely to differ from other cannabis products due to vape products’ distinctive functions (e.g., convenience, discreetness). Evidence unique to the CVPs is greatly needed to understand how this increasingly popular cannabis product is marketed to consumers to inform policy and intervention strategies. To address this research gap, this study aimed to identify and describe the product features used for marketing CVPs from a large cannabis e-commerce marketplace.

METHODS

Brand and Website Selection

We first obtained a list of 100 top-selling cannabis vape brands in the U.S. in 2023 from BDSA, a global company tracking the cannabinoid sales market.53 To compile this list, BDSA generated the dollar sales amount of all CVP brands sold in 10 states that represent some of the largest legal non-medical cannabis markets in the country (AZ, CA, CO, FL, IL, MA, MD, MI, MO, NV, NJ, NV, NY, OH, OR, PA).54 The product descriptions for CVPs were obtained from Jane Technologies (www.iheartjane.com), a large e-commerce marketplace focused on the cannabis industry, featuring 22,000 cannabis brands and 1.8 million products, with over 1.6 million verified customer reviews.55 The website has 1.3 million visits (>95% from the U.S.) per month on average and allows consumers to order cannabis products for delivery and be connected with cannabis dispensaries near them throughout the country.56 The website also provides an extensive catalog of available products (including brand, product name, product descriptions, etc.) for cannabis retailers and dispensaries to create their own product inventories on their websites.56 The information provided in their product inventory allows customers, retailers, and the public to learn about cannabis products, including product images and customer product reviews. Product information from this online retail website is also highly accessible to young people. It is documented that close to half of the adult visitors (aged ≥18) of Jane Technologies were young adults aged 18-34.57 Since the visitors just need to click “confirm” for its age verification question, “Please confirm you’re over 21 or a valid medical patient” to enter the website, it is also widely accessible to underaged minors.

Product Description Selection

Product descriptions of a sample of 343 CVPs (all regular delta-9 THC products) from 78 of the 100 top-selling cannabis vape brands – with the highest customer review ratings and recent purchases – were selected from Jane Technologies for content coding (see Figure 1 for examples of product images and descriptions). The overall goal of the search strategy was to select CVPs with the highest customer review ratings and recent purchase history to capture the recent, positively rated products sold on this platform. First, the name of the brand from the 100 top-selling list was entered into the search bar on Jane Technologies’ home page to generate a result of all products from that brand. Then, the filters “vape” and “4+ star ratings” were applied to narrow the results down to CVPs with the highest review ratings from that brand. Finally, to further narrow down products with a recent record of product reviews, the five vape products with the most customer reviews and at least one review written since January 1, 2023, were identified. This process was repeated for all brands. In some cases, less than five products from a brand were identified because all the reviews pre-dated January 1, 2023.

Figure 1.
Figure 1. Examples of Selected Cannabis Vape Product Descriptions from a Large Cannabis E-Commerce Website

To establish consistency in the selection of products, two members of the research team first worked on selecting CVPs from the same five brands and reconciled discrepancies in product selection. They then divided up the list of remaining brands evenly and independently selected products for those brands. We did not code the product reviews but used them to inform the selection of products only.

We did not include CVPs from 22 of the 100 top-selling brands due to at least one of the following reasons: (1) the brand did not feature any vape products on the website (n=10), (2) the generated products had no reviews or only had reviews written before January 1, 2023 (n=5), (3) the generated products had no reviews (n=4), or (4) the product descriptions were presented in brief bullet points that did not include adequate information related to product features for content analysis (n=3). After identifying the relevant CVPs that met the search criteria (n=343), their product descriptions were screenshotted and saved in the project folder for content coding.

Coding Procedure

A content codebook was developed using a deductive and inductive process that relied on existing research related to individuals’ expectancies for using cannabis products in general and CVPs in particular,51,52,58 and a qualitative review of product descriptions to develop and generate additional codes. Codes were also created to capture nuanced product feature categories when distinct content emerged. Three coders were trained through an iterative process of reviewing the codebook and coding the descriptions. The entire research team met to discuss the created product feature codes and their broad categories. This resulted in 24 codes across 11 product feature categories: flavor profile and sensation, psychoactive effects, product quality, mood enhancement, reduced harm, relaxation/tension reduction, therapeutic effects, focus/creativity, convenience/discreetness, socialization enhancement, and physical performance enhancement. Specific codes and their definitions are listed in Table 1. The coders then completed two rounds of double coding using a subsample (n=50 each round) of product descriptions to establish inter-rater reliability and inform codebook refinement. Each product description could be coded with as many codes as applied. Discrepancies were resolved, and the codebook was refined through discussion during the team meetings. Once Krippendorff’s alpha reached >0.80 in the second coding round,59 the remaining product descriptions were randomly split between coders. Since many states that legalized non-medical cannabis use have marketing restrictions related to using unfounded and misleading therapeutic or health claims for marketing cannabis,60 we delved into these claims to assess whether they are based on the scientific evidence related to the health benefits of cannabis use14 (see the list of such claims in Supplemental Table 1). This research involved the use of publicly available data, which is not considered human subject research under 45 CFR 46.102(d) and does not require Institutional Review Board review.

View this table:
Supplemental Table 1 Therapeutic Effect Claims for Promoting Cannabis Vape Product Descriptions a Large Cannabis E-Commerce Website
View this table:
Table 1. Product Feature Categories and Definition of Cannabis Vape Products Shown in Product Descriptions of a Large Cannabis E-Commerce Website

RESULTS

Table 1 presents the frequencies of product features found in the sample of CVP descriptions as well as detailed descriptions, definitions, and examples of those product features. The most frequent product feature category was flavor profile and sensation, referenced in 74.1% of descriptions. This category included general flavor descriptors (54.2%), fruit flavors (38.5%), flavor sensation profile (30.6%), other flavors (20.1%), concept flavors (11.9%), and flavor variety (10.8%). Psychoactive effects appeared in about half of the descriptions (47.5%) and included references to product potency (42.0%) and psychoactive effects on the user (14.6%). Product quality appeared in 42.3% of the descriptions, comprising content related to quality (23.3%), purity (16.9%), natural (14.6%), premium (11.1%), and organic (1.5%). Other product features promoted were mood enhancement (33.8%), reduced harm (24.2%), relaxation/tension reduction (23.9%), and therapeutic effects (18.4%). Therapeutic effects included mental health benefits (7.6%), non-clinical health-related content referred to as health lite (6.7%), physical health benefits (5.3%), and sleep benefits (5.0%). Less commonly promoted product features were focus/creativity (16.6%), convenience/discreetness (11.1%), socialization enhancement (6.7%), and physical performance enhancement (6.1%).

DISCUSSION

This study offers insights into how the cannabis industry promotes CVPs’ functions and benefits, which is crucial given the influence of these features on consumers’ perceptions and interest in using the products.37,38 This study identified 11 product feature categories used to promote top-selling and highly rated CVPs on a large cannabis e-commerce marketplace. The results can promote policy advances and corrective messaging to counteract the influence of the cannabis industry’s marketing strategies for promoting CVPs, a type of cannabis product increasingly gaining market share and popularity, especially among young people.

The most common product feature category promoted was flavor profile and sensation, which has previously been shown to be among the most frequently used product features in other cannabis marketing content analyses.52,61,62 Particularly salient flavor descriptors included “flavorful,” “delicious,” and “tasty,” which suggest sensory appeal. Fruit flavors were the most marketed CVP flavors in our study. Flavors in general, and fruit flavors in particular, may be especially enticing to younger people, as suggested by mounting literature related to the marketing influence of flavored tobacco products, especially flavored nicotine vape products.43,45,46 Further, research has shown that many consumers who vape cannabis, especially younger people, use flavored CVPs that taste like fruit, candy, or dessert,63 and flavors serve as an important reason for CVP initiation and susceptibility.64 Therefore, more research is needed to investigate how product features highlighting flavor sensations and specific youth-appealing flavors may promote young people’s product use to further inform marketing and labeling policies on cannabis flavors.

Psychoactive effects are another frequently used product feature for promoting CVPs. Other content analyses51,52 found that including claims and messages about the psychoactive effects of cannabis products is a common promotional tactic on cannabis retailer websites. Viewing psychoactive effect claims may heighten the intention to use the promoted products, especially because “getting high” is found to be a common motivation and reason for cannabis use.65,66 Additionally, psychoactive effect features may be particularly influential for those who are interested in using CVPs as consumers reported perceiving CVPs to produce stronger, quicker, and more favorable “highs” compared to other modes of cannabis.67,68 Recent studies have also found that the concentrates used in CVPs are much more potent than other dominant cannabis products, such as smoked products,69,70 potentially increasing the users’ risks of developing cannabis dependence.

We also found a large collection of quality-related product descriptors including the terms “quality,” “purity,” “natural,” “premium,” and “organic.” Consumers might interpret products with those claims as healthy or less harmful. Product quality descriptors are frequently used in tobacco marketing71 and can lower consumers’ perception of the tobacco products’ harm and escalate interest in using the products.72,73 This phenomenon is similar to the “health halo” effect observed in food and tobacco industry marketing74,75 where consumers may overestimate a product’s healthiness based on ingredient claims suggesting the quality or cleanness of the products. We also found several product feature claims that may directly convey reduced risks and harm from using CVPs, including “chemical free,” “no additives,” or “non-GMO.” This finding is consistent with a previous content analysis61 that found healthy ingredient descriptors (e.g., “non-GMO,” “artificial free”) to be a common type of product feature on the front of cannabis edible packages. It is concerning that these two categories of product features combined appear in more than 70% of product descriptions from our content analysis, indicating these marketing materials’ potential impact on reducing individuals’ perceived harm from CVP use. Research has already shown that many consumers view CVPs as less harmful compared to other methods of cannabis use, such as smoking.68,76 With the potential legalization of cannabis in more states, consumers may increasingly view cannabis or CVPs as not harmful or risky.77,78 More research is needed to examine the impact of viewing those claims on perceived risk and harm from CVP use to inform marketing and labeling restrictions and corrective messaging.

In addition, although cannabis was initially legalized by many states in the U.S. for its medical effects, less than 20% of the products featured claims relevant to the therapeutic effects of CVP use. These therapeutic effect claims were comprised of content about health in general (e.g., “promotes wellness”), mental health (e.g., “reduces anxiety and depression”), physical health (e.g., “aids in pain management”), and sleep benefits (e.g., “helps with insomnia”). A deeper delve into the content of those claims, however, revealed that some of them may be unfounded and misleading to consumers, especially related to the treatment of mental health conditions, which can lead to product misuse.14,79 For example, we found more than 40% of therapeutic claims were relevant to mental health conditions (e.g., anxiety and depression) and their treatment. However, substantial evidence has shown that frequent use of cannabis may increase the chance of developing mental health conditions such as anxiety80 and psychosis.81,82 This use of unfounded claims may further increase the risk that those who have mental health conditions such as depression and anxiety will use the products for symptom relief, which may exacerbate their condition. Several therapeutic claims targeted specific populations, such as patients and smokers, which may convey unfounded health benefits of CVP use among these groups who already have increased health risks. The U.S. Federal Trade Commission’s (FTC) truth-in-advertising law prohibits deceptive advertising claims regarding the safety, efficacy, and other benefits of health-related products, including cannabis.83 According to the FTC’s Health Product Compliance Guideline, companies must support health-related claims with high quality evidence.84 The FTC has taken action against companies that have failed to meet these guidelines, including sellers of cannabidiol (CBD) products promoted with unsupported health claims.85 Such monitoring of therapeutic claims used in CVP marketing materials is essential to prevent misleading information that may impact consumers’ decisions. Additional research is greatly needed to assess how these claims are interpreted by and influence the public, including those with increased health risks, to inform product marketing and labeling policies.

Many other functions and benefits found in our content analysis, such as mood enhancement, socialization enhancement, and focus/creativity, are specifically matched to cannabis use expectancies well established in previous literature.86–89 For example, mood enhancement included claims that using the product would provide positive feelings, such as euphoria or happiness; and socialization effects included claims that product use may help with friendships, romance, and closeness to others. Therefore, according to the advertising theory of the means-end approach, which posits that product features influence product use by first shaping individuals’ motives and outcome expectancies,37,38 these product features might be especially effective in promoting use interest. Research is greatly needed to investigate how= those product feature claims may affect specific cannabis-related expectancies, which may further drive product use intentions and behaviors.

Despite the vast categories of product features in place to promote CVPs, we did not find any warnings or relevant information about health risks from using CVPs that may serve to prevent product use or misuse. It has been shown that viewing either visual or textual warnings about cannabis products is associated with an increase in knowledge about health effects90 and a decrease in product appeal90,91 and use intentions.91 Providing such information can help potential consumers, especially underaged minors and those who already have physical and mental health conditions, make informed decisions when considering purchasing and using the products. Regulations that mandate warnings about potential health risks and side effects on cannabis marketing channels, especially cannabis retailer channels where consumers can directly purchase the products and with soft age gating, are greatly needed to help reduce product misuse.

The current analysis has several limitations. First, we analyzed the content of product descriptions from top-selling CVP brands with the most favorable customer reviews and recent purchase history based on the information from only one cannabis e-commerce website. Therefore, we cannot be sure that the sample of product descriptions is fully representative of CVPs of the same characteristics available in the current marketplace. Second, cannabis e-commerce websites are more likely to be visited by existing consumers of cannabis who already have purchase intentions or have used the products before. Young people who do not use cannabis, a priority population for non-medical cannabis use prevention, may be exposed to CVP marketing materials from other marketing channels (e.g., outdoor billboards and social media) that may include different product features. Lastly, this content analysis did not include information related to the packaging of CVPs, which may also contain content features that suggest product functions and benefits, such as images and text related to the flavors and therapeutic and psychoactive effects.

CONCLUSIONS

This content analysis revealed a series of product features used for marketing popular CVPs on a leading cannabis retail website. Some of these product features, such as flavor profile and sensation and psychoactive effects, may be especially appealing to youth. Some other frequently used product features, such as product quality and reduced harm, may mislead consumers to perceive the products as low-risk or healthy to use. Many product features identified are distinctly matched to various cannabis use outcome expectancies, potentially exerting a strong influence on individuals’ interest in using the products. Additional research is needed to understand the impact of promoting these product features in commercial CVP advertising to inform policy advances on product marketing and labeling, as well as corrective messaging to reduce the impact of viewing those product features on initiating and increasing product use.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

REFERENCES

  1. 1.↵
    Bryan K. Cannabis Overview. The National Conference of State Legislatures; 2024. Accessed August 27, 2024. https://www.ncsl.org/civil-and-criminal-justice/cannabis-overview
  2. 2.↵
    Rossheim ME, LoParco CR, Tillett KK, Treffers RD, Livingston MD, Berg CJ. Intoxicating Cannabis Products in Vape Shops: United States, 2023. Am J Prev Med. 2024;67(5):776–784. doi:10.1016/j.amepre.2024.07.001
    OpenUrlCrossRefPubMed
  3. 3.↵
    National Institute on Drug Abuse (NIDA). Cannabis (Marijuana). December 24, 2019. Accessed August 26, 2024. https://nida.nih.gov/publications/drugfacts/cannabis-marijuana
  4. 4.↵
  5. 5.↵
    Vetter E. Cannabis Sales by Category in 2023. MJ Platform. January 24, 2024. https://mjplatform.com/blog/cannabis-sales-by-category-in-2023/
  6. 6.↵
    A look at Cannabis Vapor Pen sales trends. Accessed July 25, 2024. https://www.headset.io/industry-reports/a-look-at-cannabis-vapor-pen-sales-trends
  7. 7.↵
    Mitchel-Chesebro B. Fastest Growing Disposable Vape Brands. BDSA. June 17, 2024. Accessed November 12, 2024. https://bdsa.com/fastest-growing-disposable-vape-brands/
  8. 8.↵
    Berg CJ, Stratton E, Schauer GL, et al. Perceived harm, addictiveness, and social acceptability of tobacco products and marijuana among young adults: marijuana, hookah, and electronic cigarettes win. Subst Use Misuse. 2015;50(1):79–89. doi:10.3109/10826084.2014.958857
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.
    Gammon DG, Gaber J, Lee YO. CBD products that resemble tobacco products enter traditional retail outlets. Tob Control. 2021;30(2):237–238. doi:10.1136/tobaccocontrol-2019-055452
    OpenUrlFREE Full Text
  10. 10.↵
    National Institute on Drug Abuse (NIDA). Marijuana and hallucinogen use among young adults reached all time-high in 2021. August 22, 2022. Accessed August 26, 2024. https://nida.nih.gov/news-events/news-releases/2022/08/marijuana-and-hallucinogen-use-among-young-adults-reached-all-time-high-in-2021
  11. 11.↵
    Miech RA, Johnston LD, Patrick ME, O’Malley PM, Bachman JG. Monitoring the Future National Survey Results on Drug Use, 1975-2023: Overview and Detailed Results for Secondary School Students. Institute for Social Research. Published online 2024. Accessed July 25, 2024. https://eric.ed.gov/?id=ED646964
  12. 12.↵
    Patrick M, Miech R, Johnston L, O’Malley P. Monitoring the Future Panel Study Annual Report: National Data on Substance Use among Adults Ages 19 to 65, 1976-2023. Institute for Social Research, University of Michigan; 2024:193.
  13. 13.↵
    Meier MH, Caspi A, Cerdá M, et al. Associations between cannabis use and physical health problems in early midlife: A longitudinal comparison of persistent cannabis vs tobacco users. JAMA Psychiatry. 2016;73(7):731–740. doi:10.1001/jamapsychiatry.2016.0637
    OpenUrlCrossRefPubMed
  14. 14.↵
    National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press (US); 2017. Accessed September 19, 2024. http://www.ncbi.nlm.nih.gov/books/NBK423845/
  15. 15.↵
    Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharma and Therapeutics. 2019;105(5):1139–1147. doi:10.1002/cpt.1381
    OpenUrlCrossRefPubMed
  16. 16.↵
    Urits I, Gress K, Charipova K, et al. Cannabis Use and its Association with Psychological Disorders. Psychopharmacol Bull. 2020;50(2):56–67.
    OpenUrlPubMed
  17. 17.↵
    Blanco C, Hasin DS, Wall MM, et al. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. JAMA Psychiatry. 2016;73(4):388–395. doi:10.1001/jamapsychiatry.2015.3229
    OpenUrlCrossRefPubMed
  18. 18.↵
    Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA psychiatry. 2016;73(3):292–297.
    OpenUrlPubMed
  19. 19.↵
    Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–1391. doi:10.1016/S0140-6736(09)61037-0
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Pomahacova B, Van Der Kooy F, Verpoorte R. Cannabis smoke condensate III: The cannabinoid content of vaporised Cannabis sativa. Inhalation Toxicology. 2009;21(13):1108–1112. doi:10.3109/08958370902748559
    OpenUrlCrossRefPubMed
  21. 21.↵
    Moir D, Rickert WS, Levasseur G, et al. A Comparison of Mainstream and Sidestream Marijuana and Tobacco Cigarette Smoke Produced under Two Machine Smoking Conditions. Chem Res Toxicol. 2008;21(2):494–502. doi:10.1021/tx700275p
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    Ott WR, Zhao T, Cheng KC, Wallace LA, Hildemann LM. Measuring indoor fine particle concentrations, emission rates, and decay rates from cannabis use in a residence. Atmospheric Environment: X. 2021;10:100106. doi:10.1016/j.aeaoa.2021.100106
    OpenUrlCrossRef
  23. 23.↵
    Liu J, Nabavizadeh P, Rao P, et al. Impairment of Endothelial Function by Aerosol From Marijuana Leaf Vaporizers. J Am Heart Assoc. 2023;12(23):e032969. doi:10.1161/JAHA.123.032969
    OpenUrlCrossRefPubMed
  24. 24.↵
    Wang X, Derakhshandeh R, Liu J, et al. One Minute of Marijuana Secondhand Smoke Exposure Substantially Impairs Vascular Endothelial Function. Journal of the American Heart Association. 2016;5(8):e003858. doi:10.1161/JAHA.116.003858
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention (US); 2014. Accessed July 7, 2023. http://www.ncbi.nlm.nih.gov/books/NBK179276/
  26. 26.
    Mermelstein R, Fiore MC, Bernstein SL, et al. Tobacco Control Research Priorities for the Next Decade: Working Group Recommendations for 2016 - 2025. National Cancer Institute Division of Cancer Control & Population Sciences; 2015:21. Accessed July 26, 2024. https://cancercontrol.cancer.gov/sites/default/files/2020-06/NCI-Tobacco-Control-Research-Priorities-Report.pdf
  27. 27.
    CDCTobaccoFree. Tobacco Industry Marketing. Centers for Disease Control and Prevention. October 20, 2023. Accessed April 8, 2024. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/tobacco_industry/marketing/index.htm
  28. 28.
    U.S. Department of Health and Human Services (HHS), Office of the Surgeon General. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health Full Report.; 2016. Accessed July 26, 2024. https://store.samhsa.gov/product/facing-addiction-america-surgeon-generals-report-alcohol-drugs-and-health-full-report/sma16-4991
  29. 29.↵
    Sargent JD, Babor TF. The Relationship Between Exposure to Alcohol Marketing and Underage Drinking Is Causal. Journal of Studies on Alcohol and Drugs Supplement. 2020;(Suppl 19):113. doi:10.15288/jsads.2020.s19.113
    OpenUrlCrossRefPubMed
  30. 30.↵
    Krauss MJ, Sowles SJ, Sehi A, et al. Marijuana advertising exposure among current marijuana users in the U.S. Drug Alcohol Depend. 2017;174:192–200. doi:10.1016/j.drugalcdep.2017.01.017
    OpenUrlCrossRefPubMed
  31. 31.
    Whitehill JM, Trangenstein PJ, Jenkins MC, Jernigan DH, Moreno MA. Exposure to Cannabis Marketing in Social and Traditional Media and Past-Year Use Among Adolescents in States With Legal Retail Cannabis. J Adolesc Health. 2020;66(2):247–254. doi:10.1016/j.jadohealth.2019.08.024
    OpenUrlCrossRefPubMed
  32. 32.↵
    Cohn AM, Alexander AC, Ehlke SJ, et al. Seeing is believing: How cannabis marketing exposure is associated with cannabis use attitudes and behavior in a permissive medical cannabis policy environment. American J Addict. 2023;32(4):333–342. doi:10.1111/ajad.13390
    OpenUrlCrossRefPubMed
  33. 33.
    Dai H. Exposure to Advertisements and Marijuana Use Among US Adolescents. Prev Chronic Dis. 2017;14:E124. doi:10.5888/pcd14.170253
    OpenUrlCrossRefPubMed
  34. 34.
    D’Amico EJ, Miles JNV, Tucker JS. Gateway to curiosity: Medical marijuana ads and intention and use during middle school. Psychol Addict Behav. 2015;29(3):613–619. doi:10.1037/adb0000094
    OpenUrlCrossRefPubMed
  35. 35.
    Trangenstein PJ, Whitehill JM, Jenkins MC, Jernigan DH, Moreno MA. Active cannabis marketing and adolescent past-year cannabis use. Drug Alcohol Depend. 2019;204:107548. doi:10.1016/j.drugalcdep.2019.107548
    OpenUrlCrossRefPubMed
  36. 36.↵
    Fiala SC, Dilley JA, Firth CL, Maher JE. Exposure to Marijuana Marketing After Legalization of Retail Sales: Oregonians’ Experiences, 2015–2016. Am J Public Health. 2018;108(1):120–127. doi:10.2105/AJPH.2017.304136
    OpenUrlCrossRefPubMed
  37. 37.↵
    Olson JC, Reynolds TJ. The means-end approach to understanding consumer decision making. Understanding consumer decision making: The means-end approach to marketing and advertising strategy. Published online 2001:3–20.
  38. 38.↵
    Reynolds TJ, Olson JC. Understanding Consumer Decision Making: The Means-End Approach to Marketing and Advertising Strategy. Psychology Press; 2001. Accessed April 9, 2024. https://books.google.com/books?hl=en&lr=&id=kjB5AgAAQBAJ&oi=fnd&pg=PP1&dq=means-end+approach+to+advertising+strategy&ots=XJE3-gdcu7&sig=07it5PEDFv9dlldAuX1ww7YaRLo
  39. 39.↵
    Anderson P, de Bruijn A, Angus K, Gordon R, Hastings G. Impact of alcohol advertising and media exposure on adolescent alcohol use: a systematic review of longitudinal studies. Alcohol Alcohol. 2009;44(3):229–243. doi:10.1093/alcalc/agn115
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.
    Lovato C, Watts A, Stead LF. Impact of tobacco advertising and promotion on increasing adolescent smoking behaviours. Cochrane Database of Systematic Reviews. 2011;(10). doi:10.1002/14651858.CD003439.pub2
    OpenUrlCrossRef
  41. 41.↵
    National Cancer Institute. The Role of the Media in Promoting and Reducing Tobacco Use. Vol 07-6242. NIH Pub; 2008. https://cancercontrol.cancer.gov/brp/tcrb/monographs/monograph-19#:∼:text=The%20Role%20of%20the%20Media%20in%20Promoting%20and
  42. 42.↵
    La Capria K, Uriarte C, Elhabashy M, et al. Exploring the Influence of E-cigarette Ad Features on Perceived Product Appeal and Use Interest Among Young Adults of Varying Tobacco-Use Behaviors. Nicotine Tob Res. Published online August 18, 2023:tad150. doi:10.1093/ntr/ntad150
    OpenUrlCrossRef
  43. 43.↵
    Chen-Sankey J, Weiger C, La Capria K, et al. Young adults’ visual attention to features of social media marketing for disposable e-cigarettes and associated perceptions. Addiction. Published online June 23, 2024. doi:10.1111/add.16586
    OpenUrlCrossRef
  44. 44.
    Chen-Sankey J, Elhabashy M, La Capria K, et al. Associations Between Noticing E-Cigarette Advertising Features and E-Cigarette Appeal and Switching Interest Among Young Adult Dual Users. Substance Use & Misuse. Published online July 8, 2024:1–12. doi:10.1080/10826084.2024.2374973
    OpenUrlCrossRef
  45. 45.↵
    Chen-Sankey J, Jeong M, Wackowski OA, et al. Noticing people, discounts and non-tobacco flavours in e-cigarette ads may increase e-cigarette product appeal among non-tobacco-using young adults. Tob Control. 2023;33(1):30–37. doi:10.1136/tobaccocontrol-2022-057269
    OpenUrlCrossRefPubMed
  46. 46.↵
    Chen-Sankey J, Weiger C, La Capria K. Using Eye tracking to Examine Young Adults’ Visual Attention to E-cigarette Advertising Features and Associated Positive E-cigarette Perceptions. Ann Behav Med. 2024;58(6):445–456. doi:10.1093/abm/kaae018
    OpenUrlCrossRefPubMed
  47. 47.↵
    Padon AA, Lochbuehler K, Maloney EK, Cappella JN. A Randomized Trial of the Effect of Youth Appealing E-Cigarette Advertising on Susceptibility to Use E-Cigarettes Among Youth. Nicotine Tob Res. 2018;20(8):954–961. doi:10.1093/ntr/ntx155
    OpenUrlCrossRefPubMed
  48. 48.↵
    Budney AJ, Sargent JD, Lee DC. Vaping cannabis (marijuana): parallel concerns to e□cigs? Addiction. 2015;110(11):1699–1704. doi:10.1111/add.13036
    OpenUrlCrossRefPubMed
  49. 49.↵
    Berg CJ, Henriksen L, Cavazos-Rehg P, Schauer GL, Freisthler B. Point-of-sale marketing and context of marijuana retailers: Assessing reliability and generalizability of the marijuana retail surveillance tool. Prev Med Rep. 2018;11:37–41. doi:10.1016/j.pmedr.2018.05.010
    OpenUrlCrossRefPubMed
  50. 50.
    Berg CJ, Romm KF, Pannell A, et al. Cannabis retailer marketing strategies and regulatory compliance: A surveillance study of retailers in 5 US cities. Addict Behav. 2023;143:107696. doi:10.1016/j.addbeh.2023.107696
    OpenUrlCrossRefPubMed
  51. 51.↵
    Cavazos-Rehg PA, Krauss MJ, Cahn E, et al. Marijuana Promotion Online: an Investigation of Dispensary Practices. Prev Sci. 2019;20(2):280–290. doi:10.1007/s11121-018-0889-2
    OpenUrlCrossRefPubMed
  52. 52.↵
    Luc MH, Tsang SW, Thrul J, Kennedy RD, Moran MB. Content analysis of online product descriptions from cannabis retailers in six US states. Int J Drug Policy. 2020;75:102593. doi:10.1016/j.drugpo.2019.10.017
    OpenUrlCrossRefPubMed
  53. 53.↵
    BDSA. Cannabis Industry Data Analytics & Business Intelligence. Accessed November 12, 2024. https://bdsa.com/
  54. 54.↵
    BDSA. Unmatched Global Cannabinoid Market Research. BDSA Internal Report. 2024.
  55. 55.↵
    Shop cannabis dispensaries and brand deals near me. iheartjane. Accessed June 26, 2024. https://www.iheartjane.com
  56. 56.↵
    Point of Sale. iheartjane. Accessed November 12, 2024. https://www.iheartjane.com/pos
  57. 57.↵
    iheartjane.com Website Analysis for October 2024. Similarweb. 2024. Accessed November 11, 2024. https://www.similarweb.com/website/iheartjane.com/
  58. 58.↵
    Kowitt SD, Yockey RA, Lee JGL, Jarman KL, Gourdet CK, Ranney LM. The Impact of Cannabis Packaging Characteristics on Perceptions and Intentions. Am J Prev Med. 2022;63(5):751–759. doi:10.1016/j.amepre.2022.04.030
    OpenUrlCrossRefPubMed
  59. 59.↵
    Krippendorff K. Content Analysis: An Introduction to Its Methodology. Fourth Edition. SAGE Publications; 2018. doi:10.4135/9781071878781
    OpenUrlCrossRef
  60. 60.↵
    Swinburne MR, Liu S. State Regulation of Adult-Use Cannabis Advertising. The Network for Public Health Law; 2022. https://www.networkforphl.org/wp-content/uploads/2022/11/State-Regulation-of-Adult-Use-Cannabis-Advertising.pdf
  61. 61.↵
    Reboussin BA, Lazard AJ, Ross JC, et al. A content analysis of cannabis edibles package marketing in the United States. International Journal of Drug Policy. 2024;130:104526. doi:10.1016/j.drugpo.2024.104526
    OpenUrlCrossRefPubMed
  62. 62.↵
    Tan AS, Weinreich E, Padon A, et al. Presence of Content Appealing to Youth on Cannabis-Infused Edibles Packaging. Subst Use Misuse. 2022;57(8):1215–1219. doi:10.1080/10826084.2022.2069268
    OpenUrlCrossRefPubMed
  63. 63.↵
    D’Mello K, Chan GCK, Hall W, Rychert M, Wilkins C, Hammond D. Use of flavored cannabis vaping products in the US, Canada, Australia, and New Zealand: findings from the international cannabis policy study wave 4 (2021). The American Journal of Drug and Alcohol Abuse. 2023;49(5):640–651. doi:10.1080/00952990.2023.2238116
    OpenUrlCrossRefPubMed
  64. 64.↵
    Chaffee BW, Couch ET, Wilkinson ML, et al. Flavors increase adolescents’ willingness to try nicotine and cannabis vape products. Drug Alcohol Depend. 2023;246:109834. doi:10.1016/j.drugalcdep.2023.109834
    OpenUrlCrossRefPubMed
  65. 65.↵
    Bray BC, Berglund PA, Evans-Polce RJ, Patrick ME. A Latent Transition Analysis of Self-Reported Reasons for Marijuana Use During Young Adulthood. Eval Health Prof. 2021;44(1):9–24. doi:10.1177/0163278720984514
    OpenUrlCrossRefPubMed
  66. 66.↵
    Patrick ME, Bray BC, Berglund PA. Reasons for Marijuana Use Among Young Adults and Long-Term Associations With Marijuana Use and Problems. J Stud Alcohol Drugs. 2016;77(6):881–888. doi:10.15288/jsad.2016.77.881
    OpenUrlCrossRefPubMed
  67. 67.↵
    Morean ME, Lipshie N, Josephson M, Foster DW. Predictors of adult e-cigarette users vaporizing cannabis using e-cigarettes and vape-pens. Subst Use Misuse. 2017;52(8):974–981. doi:10.1080/10826084.2016.1268162
    OpenUrlCrossRefPubMed
  68. 68.↵
    Aston ER, Farris SG, Metrik J, Rosen RK. Vaporization of Marijuana Among Recreational Users: A Qualitative Study. Journal of Studies on Alcohol and Drugs. 2019;80(1):56. doi:10.15288/jsad.2019.80.56
    OpenUrlCrossRef
  69. 69.↵
    Hasin DS, Borodovsky J, Shmulewitz D, et al. Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws. Drug and Alcohol Dependence. 2021;229:109159. doi:10.1016/j.drugalcdep.2021.109159
    OpenUrlCrossRefPubMed
  70. 70.↵
    Spindle TR, Cone EJ, Schlienz NJ, et al. Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: A crossover trial. JAMA Netw Open. 2018;1(7):e184841. doi:10.1001/jamanetworkopen.2018.4841
    OpenUrlCrossRef
  71. 71.↵
    Moran MB, Pierce JP, Weiger C, Cunningham MC, Sargent JD. Use of imagery and text that could convey reduced harm in American Spirit advertisements. Tob Control. 2017;26(e1):e68–e70. doi:10.1136/tobaccocontrol-2016-053251
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    Sanders-Jackson A, Tan ASL, Yie K. Effects of health-oriented descriptors on combustible cigarette and electronic cigarette packaging: an experiment among adult smokers in the United States. Tobacco Control. 2018;27(5):534–541. doi:10.1136/tobaccocontrol-2017-053795
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    Baig SA, Byron MJ, Lazard AJ, Brewer NT. “Organic,” “Natural,” and “Additive-Free” Cigarettes: Comparing the Effects of Advertising Claims and Disclaimers on Perceptions of Harm. Nicotine Tob Res. 2018;21(7):933–939. doi:10.1093/ntr/nty036
    OpenUrlCrossRef
  74. 74.↵
    Williams P. Consumer Understanding and Use of Health Claims for Foods. Nutrition Reviews. 2005;63(7):256–264. doi:10.1111/j.1753-4887.2005.tb00382.x
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    Iles IA, Pearson JL, Lindblom E, Moran MB. “Tobacco and Water”: Testing the Health Halo Effect of Natural American Spirit Cigarette Ads and Its Relationship with Perceived Absolute Harm and Use Intentions. Health Communication. 2021;36(7):804–815. doi:10.1080/10410236.2020.1712526
    OpenUrlCrossRefPubMed
  76. 76.↵
    Lee DC, Crosier BS, Borodovsky JT, Sargent JD, Budney AJ. Online survey characterizing vaporizer use among cannabis users. Drug and Alcohol Dependence. 2016;159:227–233. doi:10.1016/j.drugalcdep.2015.12.020
    OpenUrlCrossRefPubMed
  77. 77.↵
    Pacek LR, Mauro PM, Martins SS. Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity. Drug and alcohol dependence. 2015;149:232–244. doi:10.1016/j.drugalcdep.2015.02.009
    OpenUrlCrossRefPubMed
  78. 78.↵
    Levy NS, Mauro PM, Mauro CM, Segura LE, Martins SS. Joint perceptions of the risk and availability of cannabis in the United States, 2002-2018. Drug and alcohol dependence. 2021;226:108873. doi:10.1016/j.drugalcdep.2021.108873
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Teutsch S,
    2. Hurd Y,
    3. Boyle E
    , eds. Cannabis Policy Impacts Public Health and Health Equity. National Academies Press; 2024. doi:10.17226/27766
    OpenUrlCrossRef
  80. 80.↵
    Bataineh BS, Wilkinson AV, Sumbe A, et al. The Association Between Tobacco and Cannabis Use and the Age of Onset of Depression and Anxiety Symptoms: Among Adolescents and Young Adults. Nicotine & Tobacco Research. 2023;25(8):1455–1464. doi:10.1093/ntr/ntad058
    OpenUrlCrossRefPubMed
  81. 81.↵
    Urits I, Gress K, Charipova K, et al. Cannabis use and its association with psychological disorders. Psychopharmacology bulletin. 2020;50(2):56.
    OpenUrlPubMed
  82. 82.↵
    Blanco C, Hasin DS, Wall MM, et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA psychiatry. 2016;73(4):388–395.
    OpenUrlCrossRefPubMed
  83. 83.↵
    What’s new – and what isn’t – in the FTC’s just-published Health Products Compliance Guidance. Federal Trade Commission. December 15, 2022. Accessed November 11, 2024. https://www.ftc.gov/business-guidance/blog/2022/12/whats-new-what-isnt-ftcs-just-published-health-products-compliance-guidance
  84. 84.↵
    Health Products Compliance Guidance. Federal Trade Commission. December 20, 2022. Accessed November 11, 2024. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
  85. 85.↵
    FTC Announces Crackdown on Deceptively Marketed CBD Products. Federal Trade Commission. December 16, 2020. Accessed November 11, 2024. https://www.ftc.gov/news-events/news/press-releases/2020/12/ftc-announces-crackdown-deceptively-marketed-cbd-products
  86. 86.↵
    Simons J, Correia CJ, Carey KB, Borsari BE. Validating a five-factor marijuana motives measure: Relations with use, problems, and alcohol motives. Journal of Counseling Psychology. 1998;45(3):265–273. doi:10.1037/0022-0167.45.3.265
    OpenUrlCrossRef
  87. 87.
    Lee CM, Neighbors C, Woods BA. Marijuana motives: young adults’ reasons for using marijuana. Addict Behav. 2007;32(7):1384–1394. doi:10.1016/j.addbeh.2006.09.010
    OpenUrlCrossRefPubMed
  88. 88.
    Torrealday O, Stein L a. R, Barnett N, et al. Validation of the Marijuana Effect Expectancy Questionnaire-Brief. J Child Adolesc Subst Abuse. 2008;17(4):1–17. doi:10.1080/15470650802231861
    OpenUrlCrossRefPubMed
  89. 89.↵
    Buckner JD, Ecker AH, Welch KD. Psychometric properties of a valuations scale for the Marijuana Effect Expectancies Questionnaire. Addict Behav. 2013;38(3):1629–1634. doi:10.1016/j.addbeh.2012.10.010
    OpenUrlCrossRefPubMed
  90. 90.↵
    Mutti-Packer S, Collyer B, Hodgins DC. Perceptions of plain packaging and health warning labels for cannabis among young adults: findings from an experimental study. BMC Public Health. 2018;18(1):1361. doi:10.1186/s12889-018-6247-2
    OpenUrlCrossRefPubMed
  91. 91.↵
    Yang S, Cotter LM, Lu L, et al. Countering online marketing and user endorsements with enhanced cannabis warning labels: An online experiment among at-risk youth and young adults. Preventive Medicine. 2024;180:107877. doi:10.1016/j.ypmed.2024.107877
    OpenUrlCrossRefPubMed
Back to top
Posted November 14, 2024.
Download PDF
Data/Code
Email
Product Features Used to Promote Top-selling Cannabis Vape Products in An Online Retail Environment
Julia Chen-Sankey, Kathryn La Capria, Siyan Meng, Rosanna Mazzeo, Neha Vijayakumar, Alisa A. Padon, Kimberly G. Wagoner, Meghan B. Moran, Matthew Rossheim, Carla Berg, Kristina M. Jackson
medRxiv 2024.11.13.24317258; doi: https://doi.org/10.1101/2024.11.13.24317258
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area